A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to determine the safety and potential efficacy of
sustained-release bupropion (Zyban®) for the treatment of nicotine dependence in patients
with bipolar affective illness. It is hypothesized that bupropion will produce a significant
enhancement of smoking abstinence compared to placebo and will be safe for use in these
patients.